Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
MWN-AI** Summary
Nyxoah SA, a Belgian medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA), has announced its intent to release financial results for the fourth quarter and full year of 2025 on March 19, 2026. Following the announcement, company management will host a conference call at 10:30 PM CET (4:30 PM ET) to discuss these results. Interested parties can access the call via a webcast on Nyxoah's Investor Relations webpage, with instructions provided for those wishing to participate actively by asking questions.
Nyxoah's flagship product, the Genio system, represents a breakthrough in the treatment of OSA, utilizing leadless and battery-free hypoglossal neurostimulation. This therapy targets one of the most prevalent sleep-related breathing conditions associated with serious health risks. The Genio system received its European CE Mark in 2019, and following the BETTER SLEEP study, its indications expanded to include patients with Complete Concentric Collapse (CCC). In August 2025, Nyxoah also attained FDA approval for the device to be prescribed to specific adult patients with moderate to severe OSA.
The company has undergone significant growth, having completed successful IPOs on both Euronext Brussels and NASDAQ. The forthcoming financial results announcement is particularly significant as it comes after a year marked by promising study outcomes that could strengthen its market position against competitors. Stakeholders and investors will be keen to assess Nyxoah's financial performance and strategic plans moving forward, which may reflect the company's evolving role in the OSA treatment landscape.
For further inquiries, Nyxoah has provided contact information for its CFO and Head of Investor Relations, demonstrating transparency and commitment to stakeholder engagement as it moves into 2026.
MWN-AI** Analysis
As Nyxoah prepares to release its fourth quarter and full year financial results for 2025 on March 19, 2026, investors should approach this event with careful consideration of several key factors that could impact the company's market performance.
Nyxoah specializes in innovative therapies for Obstructive Sleep Apnea (OSA), with its flagship product, the Genio system, which is a leadless and battery-free hypoglossal neurostimulation device. The recent FDA approval for select patients and positive studies such as the BETTER SLEEP and DREAM IDE highlight the company’s strengthening position in a high-demand market, particularly as competition in the OSA treatment arena is poised to intensify.
Before the earnings call, it’s prudent for investors to analyze the previous quarters’ performance metrics, focusing on revenue growth trends, profitability, and market share advancements. The anticipated financial results and any guidance offered during the conference call will be critical indicators for the company's outlook and by extension, the stock’s valuation.
Additionally, since Nyxoah has recently expanded its therapeutic indications, updates regarding patient enrollment, regulatory interactions, and any strategic partnerships will likely play a role in shaping future projections. Pay attention to management’s commentary on market penetration strategies, especially in the U.S., which could signal growth potential.
Investors should remain cautious of the inherent risks articulated in Nyxoah’s disclosures, particularly those surrounding market dynamics and competitive pressures. The nuanced nature of healthcare technologies often results in stock volatility, particularly around earnings announcements.
A strategic approach—monitoring the earnings release closely and considering market reactions—will be essential in navigating any potential investment decisions regarding Nyxoah stock post-reporting.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 and FY 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Nyxoah's Q4 and FY 2025 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
The archived webcast will be available for replay shortly after the close of the call.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Rémi Renard
Head of Investor Relations & Corporate Communication
IR@nyxoah.com
Attachment
FAQ**
What key performance metrics will Nyxoah SA NYXH highlight in the fourth quarter and full year 2025 financial results, and how do they compare to the previous fiscal year?
Can you provide an update on the market response to the Genio system now that it is FDA approved and any insights on its commercialization strategy moving forward?
In light of the recent CE mark expansion for complete concentric collapse patients, what strategies does Nyxoah SA NYXH have in place to capture this new market segment?
What are the major challenges Nyxoah SA NYXH anticipates facing in 2026 regarding competition and demand for its products, and how does the company plan to address them?
**MWN-AI FAQ is based on asking OpenAI questions about Nyxoah SA (NASDAQ: NYXH).
NASDAQ: NYXH
NYXH Trading
-5.96% G/L:
$3.47 Last:
38,712 Volume:
$3.66 Open:
